Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15799974 | 0.89 | GAA (0.45) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL769867 | 0.86 | MAPT (0.60) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL2069436 | 0.82 | MAPT (0.54) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL769402 | 0.74 | MAPT (0.51) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL15213087 | 0.73 | MEN1 (0.44) | MAPTALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL15213056 | 0.71 | HPGD (0.44) | MAPTGAAALDH1A1HPGDNPC1 | |
| SCHEMBL15213057 | 0.71 | ALDH1A1 (0.48) | MAPTKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL2067541 | 0.70 | NPC1 (0.45) | MAPTGAAKDM4EALDH1A1HPGD | |
| SCHEMBL15213060 | 0.70 | HPGD (0.56) | MAPTKDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL15213059 | 0.69 | HPGD (0.55) | MAPTALDH1A1HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754082-B2 | Antiviral drugs for treatment of Arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-06-17 | — | — | US | claimed |
| US-20140128426-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2014-05-08 | — | — | US | claimed |
| EP-2182805-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC (US) | 2013-06-26 | — | — | EP | claimed |
| US-8461177-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | claimed |
| US-9096597-B2 | Antiviral drugs for treatment of Arenavirus infection | Kineta Four, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096597-B2 | Antiviral drugs for treatment of Arenavirus infection | Kineta Four, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096597-B2 | Antiviral drugs for treatment of Arenavirus infection | Kineta Four, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754082-B2 | Antiviral drugs for treatment of Arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140128426-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2182805-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8461177-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461177-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-8461177-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064693-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | EIF2AK2, ZC3HAV1, SARS1 | MAPT 4118/4885GAA 27/4885KDM4E 4051/4885 |
| US-20140128426-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | EIF2AK2, ZC3HAV1, SARS1 | MAPT 4118/4885GAA 27/4885KDM4E 4051/4885 |
| US-20140243367-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | MAPT 4118/4885GAA 27/4885KDM4E 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.